LAKE FOREST, Calif., March 9 /PRNewswire/ -- HemoCue, Inc., a leader in advanced point-of-care testing (POCT) systems, announced today that they have been approved by the American Red Cross, to be added to their vendor list. Don DuBois, General Manager of HemoCue, Inc. stated, "I am honored and excited to have signed this contract with the American Red Cross."
The HemoCue Donor Hb Checker system was designed specifically for blood banks, taking into consideration key concerns such as accuracy, precision, and deferral rates. Recent studies looking at deferral rates have shown that switching to the HemoCue Donor Hb Checker system from microhematocrit methods may reduce donor deferral rates. Using an accurate, objective, and reliable hemoglobin testing method along with a good sampling technique can protect donors from inappropriately being allowed to donate, while still optimizing the deferral rate.
The Donor Hb Checker system requires minimal maintenance, minimum handling of blood, eliminates the concerns associated with the disposal of copper sulfate, and eliminates the risks and subjectivity associated with microhematocrit methods.
About HemoCue
HemoCue is a leader in the development, manufacturing, and marketing of advanced medical testing systems that bring lab-quality results to the point-of-care. Its leading products include hemoglobin, glucose, and urine albumin point-of-care testing systems. The fundamental concept behind HemoCue's products is the ability to perform common blood and urine tests at the point-of-care without sacrificing the accuracy and precision offered by a central clinical lab.
HemoCue is owned by EQT, a leading private equity group in Northern Europe.
For additional information about HemoCue, or its products and services, visit http://www.hemocue.com.
HemoCue, Inc.CONTACT: Lily Sunkin, National Marketing Manager of HemoCue, Inc.,+1-800-861-1611, or +1-949-859-2630, lily@hemocue.com
Web site: http://www.hemocue.com/
